Meitav Investment House’s Moderna MRNA Stock Holding History

Meitav Investment House’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Hold	27,143	–	–	0.01%	195
2026 Q1	$1.38M	Sell	27,143 -16,067	-37%	-$750K	0.02%	148
2025 Q4	$1.27M	Hold	43,210	–	–	0.01%	162
2025 Q3	$1.12M	Hold	43,210	–	–	0.01%	161
2025 Q2	$1.19M	Hold	43,210	–	–	0.02%	142
2025 Q1	$1.23M	Buy	43,210 +350	+0.8%	+$12.4K	0.02%	124
2024 Q4	$1.78M	Sell	42,860 -184,043	-81%	-$8.8M	0.03%	114
2024 Q3	$15.2M	Buy	226,903 +111,475	+97%	+$10.2M	0.25%	71
2024 Q2	$13.7M	Sell	115,428 -51,978	-31%	-$6.58M	0.24%	70
2024 Q1	$17.8M	Buy	167,406 +96	+0.1%	+$9.68K	0.35%	66
2023 Q4	$16.6M	Buy	167,310 +16	+0%	+$1.35K	0.24%	87
2023 Q3	$16.9M	Buy	167,294 +12,189	+8%	+$1.36M	0.27%	84
2023 Q2	$18.9M	Hold	155,105	–	–	0.3%	83
2023 Q1	$20.8M	Buy	155,105 +132,259	+579%	+$21.8M	0.36%	77
2022 Q4	$4.1M	Hold	22,846	–	–	0.07%	151
2022 Q3	$2.7M	Buy	22,846 +65	+0.3%	+$9.86K	0.05%	177
2022 Q2	$3.25M	Buy	22,781 +7,839	+52%	+$1.12M	0.06%	166
2022 Q1	$2.57M	Buy	+14,942	New	+$2.52M	0.04%	200

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Meitav Investment House's MRNA Position: Q2 2026 in Review

Meitav Investment House held its Moderna (MRNA) position steady in Q2 2026 at 27,143 shares worth $1.9M. The position accounts for 0.01% of the portfolio, ranked #195.

Meitav Investment House first reported a position in MRNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $20.8M in Q1 2023. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Meitav Investment House held 27,143 shares of Moderna worth $1.9M as of Q2 2026.
Meitav Investment House left its Moderna share count unchanged in Q2 2026.
Moderna made up 0.01% of Meitav Investment House's portfolio in Q2 2026, its #195 holding.
Meitav Investment House first reported a position in Moderna in Q1 2022 and has held it in 18 quarters since.
Meitav Investment House's Moderna position peaked at $20.8M in Q1 2023.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Meitav Investment House's 13F filing for Q2 2026, filed 20 Jul 2026.